Cox 2 Inhibitor News and Research

RSS

Cox-2 Inhibitors are nonsteroidal anti-inflammatory drugs used to relieve pain and inflammation. COX-2 inhibitors are being studied in the prevention of colon polyps, and as anticancer drugs. Also called cyclo-oxygenase-2 inhibitor.

Former smokers with lung cancer can benefit from celecoxib treatment

Celecoxib may emerge as a potent chemopreventive agent for lung cancer, according to a recent study in Cancer Prevention Research, a journal of the American Association for Cancer Research.

6 Jul 2011

Change in diet can reduce cancer risk

Eating a low-carbohydrate, high-protein diet may reduce the risk of cancer and slow the growth of tumors already present, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.

15 Jun 2011

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Tragara Pharmaceuticals, Inc. announced today that apricoxib in combination with erlotinib demonstrated significant and consistent clinical benefit over erlotinib alone in a clinically relevant subset of biomarker-selected patients with non-small cell lung cancer (NSCLC) who had previously failed a platinum-containing regimen for advanced disease.

7 Jun 2011

CrystalGenomics begins enrollment in CG100649 Phase 2b osteoarthritis study

CrystalGenomics, Inc. and CG Pharmaceuticals, Inc., a biopharmaceutical company with 3 clinical stage candidates, has announced that the first patient has been enrolled for a Phase 2b clinical study of CG100649, CrystalGenomics' clinical stage novel NSAID candidate, in patients with knee or hip osteoarthritis.

1 Jun 2011

Anti-inflammatory drug celecoxib reacts with protein and induces liver cancer cells to commit suicide

The anti-inflammatory drug celecoxib, known by the brand name Celebrex, triggers liver cancer cell death by reacting with a protein in a way that makes those cells commit suicide, according to a new study.

17 May 2011

Research finds 'no safe window' for painkiller use among heart attack survivors

Even short-term use of some painkillers could be dangerous for people who've had a heart attack, according to research published in Circulation: Journal of the American Heart Association.

10 May 2011

New research: Fluid retention may explain drugs' risk of strokes and heart attacks

New research shows that medications which have raised safety concerns over heart attack and stroke risks may not have gotten approval from the Food and Drug Administration if the cardiovascular effects of fluid retention had been better understood. Fluid retention may explain the increased risk of heart attacks and strokes of medications such as Vioxx, Bextra, and Avandia.

22 Feb 2011

$Tip sheets provide details on hip and knee fracture treatment$

Tip sheets provide details on hip and knee fracture treatment

Patients who wait more than 36 hours for surgery to correct a hip fracture have a 39 percent rate of medical complication and those who wait 48 hours have a 46 percent complication rate. Patients who receive surgical treatment within 24 hours have a lower complication rate of 25 percent and a shorter hospital stay. Each day the surgery was delayed added an additional two days to hospital stay.

21 Feb 2011

Painkillers and heart attack risk

A new study has shown that taking certain commonly used painkillers for long periods or in high doses increases the risk of heart attacks or strokes. The study comes from researchers from Bern University and is published in the British Medical Journal.

16 Jan 2011

Unintended direct conflict between pharmaceutical marketing and public health

Drugs that pharmaceutical companies market most aggressively to physicians and patients tend to offer less benefit and more harm to most patients - a phenomenon described as the "inverse benefit law" in a paper from the University of Texas Medical Branch at Galveston.

14 Jan 2011

Patients who consume painkillers may face cardiovascular risk

The drugs include traditional non-steroidal anti-inflammatory drugs as well as new generation anti-inflammatory drugs, known as COX-2 inhibitors. The researchers say that doctors and patients need to be aware that prescription of any anti-inflammatory drug needs to take cardiovascular risk into account.

12 Jan 2011

Exemestane may provide post-surgery option for postmenopausal women with hormone-receptor positive breast cancer

Exemestane, an aromatase inhibitor that blocks production of estrogen, may provide another post-surgery option for postmenopausal women with hormone-receptor positive, early-stage breast cancer.

13 Dec 2010

Low-dose diazepam with NS-398 combination has twice the neuroprotective effect of NS-398 alone

Status epilepticus, prolonged seizures, can lead to significant neurological deficits and, rarely, even death. The anticonvulsant diazepam, a first line therapy for the condition, is neuroprotective when administered in high doses within two hours from seizure onset. Researchers at the 64th AES Annual Meeting now report that the combination of low-dose diazepam and NS-398, a COX-2 inhibitor, has twice the neuroprotective effect of NS-398 alone.

8 Dec 2010

Arthritis drug reduces incidence of non-melanoma skin cancers

A widely-used arthritis drug reduces the incidence of non-melanoma skin cancers - the most common cancers in humans - according to a study published this week in the Journal of the National Cancer Institute. The COX-2 inhibitor celecoxib (brand name Celebrex), which is currently approved for the treatment of osteoarthritis, rheumatoid arthritis and acute pain in adults led to a 62 percent reduction in non-melanoma skin cancers, which includes basal cell carcinomas and squamous cell carcinomas.

3 Dec 2010

CrystalGenomics to present Phase I MAD study data at Arrowhead Summit

CrystalGenomics, Inc. and CG Pharmaceuticals, Inc. a drug discovery and development biopharmaceutical company, has announced that Dr. William Schmidt, its Vice President of Clinical Development, has been invited to present a talk on Development of CG100649, Tissue-selective Dual Inhibitor of COX-2 and Carbonic Anhydrase for Treatment of Osteoarthritis at Arrowhead's upcoming 4th Annual Pain Therapeutics Summit, to be held on October 4-5, 2010 in Philadelphia.

5 Oct 2010

Sanford-Burnham receives five-year core grant renewal from NCI

The Cancer Center at Sanford-Burnham Medical Research Institute (Sanford-Burnham) has received a five-year core grant renewal from the National Cancer Institute (NCI).

29 Sep 2010

BCM-95 curcumin exhibits anti-inflammatory properties

Top researchers at the Gastrointestinal Cancer Research Lab at Baylor University Medical Center in Dallas are exploring the clinical applications of BCM-95®, a new patented extract of curcumin with unprecedented potency, and bioavailability.

17 Sep 2010

Etoricoxib better than opioid drug tramadol for postoperative pain: Study

For patients with moderate pain after foot surgery, the cyclo-oxygenase 2 (COX-2) inhibitor drug etoricoxib provides better pain relief with fewer side effects than the opioid drug tramadol, concludes a study in the August issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

3 Aug 2010

Fluorescent inhibitors hold promise for early-stage tumor detection

A series of novel imaging agents could light up tumors as they begin to form - before they turn deadly - and signal their transition to aggressive cancers.

29 Apr 2010

Celebrex stops aspirin from doing its job effectively

Millions of Americans take Celebrex for arthritis or other pain. Many, if they are middle-aged or older, also take a low-dose aspirin tablet daily to reduce the risk of heart attack and stroke. Yet they may be getting little protection, because Celebrex keeps the aspirin from doing its job effectively, a new study suggests.

15 Dec 2009